Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqing Lou

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 2, 2011
Association between the angiotensinogen gene T174M polymorphism and hypertension risk in the Chinese population: a meta-analysisWei Gu, Ya Liu, Zuoguang Wang, et al.
Chemosphere|November 8, 2024
Evaluating AGS efficiency in PHA synthesis and extraction integrated with nutrient removal: The impact of COD concentrationsQuan Yuan, Song Chen, Yun Chen, et al.
Oncotarget|September 17, 2016
Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutationsJianlin Xu, Xueyan Zhang, Haitang Yang, et al.
Frontiers in Cell and Developmental Biology|April 1, 2022
Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia SignalsYuqing Lou, Qin Shi, Yanwei Zhang, et al.
Cancer Cell International|January 7, 2021
PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathwayWei Zhang, Yanwei Zhang, Wensheng Zhou, et al.
Oncotargets and Therapy|November 2, 2016
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of ChinaJianlin Xu, Guozheng Ding, Xueyan Zhang, et al.
Cancer Letters|February 17, 2022
The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinomaYuqing Lou, Jun Lu, Yanwei Zhang, et al.
Journal of Cellular and Molecular Medicine|February 20, 2020
Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinomaMinjuan Hu, Yanwei Zhang, Beibei Sun, et al.
Plos One|October 8, 2010
Alpha-adducin Gly460Trp polymorphism and hypertension risk: a meta-analysis of 22 studies including 14303 cases and 15961 controlsKuo Liu, Jielin Liu, Yan Huang, et al.
Scientific Reports|December 2, 2016
Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutationJianlin Xu, Haitang Yang, Bo Jin, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 2, 2011
Association between the angiotensinogen gene T174M polymorphism and hypertension risk in the Chinese population: a meta-analysisWei Gu, Ya Liu, Zuoguang Wang, et al.
Chemosphere|November 8, 2024
Evaluating AGS efficiency in PHA synthesis and extraction integrated with nutrient removal: The impact of COD concentrationsQuan Yuan, Song Chen, Yun Chen, et al.
Oncotarget|September 17, 2016
Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutationsJianlin Xu, Xueyan Zhang, Haitang Yang, et al.
Frontiers in Cell and Developmental Biology|April 1, 2022
Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia SignalsYuqing Lou, Qin Shi, Yanwei Zhang, et al.
Cancer Cell International|January 7, 2021
PlGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/β-catenin pathwayWei Zhang, Yanwei Zhang, Wensheng Zhou, et al.
Oncotargets and Therapy|November 2, 2016
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of ChinaJianlin Xu, Guozheng Ding, Xueyan Zhang, et al.
Cancer Letters|February 17, 2022
The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinomaYuqing Lou, Jun Lu, Yanwei Zhang, et al.
Journal of Cellular and Molecular Medicine|February 20, 2020
Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinomaMinjuan Hu, Yanwei Zhang, Beibei Sun, et al.
Plos One|October 8, 2010
Alpha-adducin Gly460Trp polymorphism and hypertension risk: a meta-analysis of 22 studies including 14303 cases and 15961 controlsKuo Liu, Jielin Liu, Yan Huang, et al.
Scientific Reports|December 2, 2016
Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutationJianlin Xu, Haitang Yang, Bo Jin, et al.
Pageof 12